Back to All NewsAllergan Launches Juvéderm® VOLITE
Posted By American Med Spa Association, Friday, January 27, 2017
Share
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today its entry into the skin quality category with the launch of Juvéderm® VOLITE. This is Allergan's first injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session.This innovative new Allergan product uses the unique patented VYCROSS® technology.
A new innovation for skin quality
The new HA injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity, and is designed to last for up to nine months with just one treatment. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing. Juvéderm® VOLITE aims to deliver results that last and eliminate the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands and contains the anaesthetic lidocaine, to enhance patient comfort.
Read more at PRNewswire >>
A new innovation for skin quality
The new HA injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity, and is designed to last for up to nine months with just one treatment. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing. Juvéderm® VOLITE aims to deliver results that last and eliminate the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands and contains the anaesthetic lidocaine, to enhance patient comfort.
Read more at PRNewswire >>
